Trial Profile
Study 200977: Albiglutide + Insulin Glargine Versus Insulin Lispro + Insulin Glargine in the Treatment of Subjects With Type 2 Diabetes Mellitus: The Switch Study
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 22 Aug 2023
Price :
$35
*
At a glance
- Drugs Albiglutide (Primary) ; Insulin glargine; Insulin lispro
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms The Switch Study
- Sponsors GlaxoSmithKline; GSK
- 12 Jul 2020 Results assessing the efficacy and safety of substituting prandial insulin with a weekly GLP-1RA in people with type 2 diabetes with inadequately controlled blood glucose levels published in the Diabetes Care
- 05 Oct 2018 Results assessing Basal/bolus insulin optimization during a 4-week run-in phase before randomization presented at the 54th Annual Meeting of the European Association for the Study of Diabetes.
- 05 Oct 2018 Primary endpoint has been met. (Change from Baseline in glycosylated hemoglobin HbA1c at Week 26)